Prolacta Bioscience, a privately held company that provides specialty formulations of human milk for the immunological and nutritional needs of premature and critically ill infants, announced today that it has raised over $5 million in private venture funding for its series B prime financing round from a combination of existing investors, new investors, and several high profile angel investors.
New investors included Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, and the Gideon Hixon Fund. Existing investors include DFJ Frontier, Draper Richards, and Draper Associates.
click to read more...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment